Diffuse large B-cell lymphoma variants: an update

References

1. Swerdlow S.H. Campo E. Harris N.L. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. IARC, Lyon2017
   View in Article

   • Google Scholar
2. • Li S.
   • Young K.H.
   • Medeiros L.J.
   Diffuse large B-cell lymphoma.
   Pathology. 2018; 50: 74-87
   View in Article

   • Google Scholar
3. • Kommalapati A.
   • Tella S.H.
   • Go R.S.
   • et al.
   T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes.
   Br J Haematol. 2019; 185: 140-142
   View in Article

   • Google Scholar
4. • Abramson J.S.
   T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
   Oncologist. 2006; 11: 384-392
   View in Article

   • Google Scholar
5. • Tian X.
   • Xu J.
   • Dorfman D.M.
   Utility of combined EZH2, p-ERK1/2, p-STAT, and MYC expression in the differential diagnosis of EZH2-positive Hodgkin lymphomas and related large B-cell lymphomas.
   Am J Surg Pathol. 2019; 43: 102-109
   View in Article

   • Google Scholar
6. • Kunder C.
   • Cascio M.J.
   • Bakke A.
   • et al.
   Predominance of CD4+ T cells in T-cell/histiocyte-rich large B-cell lymphoma and identification of a subset of patients with peripheral B-cell lymphopenia.
   Am J Clin Pathol. 2017; 147: 596-603
   View in Article

   • Google Scholar
7. • Felgar R.E.
   • Steward K.R.
   • Cousar J.B.
   • et al.
   T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas.
   Am J Pathol. 1998; 153: 1707-1715
   View in Article

   • Google Scholar
8. • Nam-Cha S.H.
   • Roncador G.
   • Sanchez-Verde L.
   • et al.
   PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma.
   Am J Surg Pathol. 2008; 32: 1252-1257
   View in Article

   • Google Scholar
9. • Schuhmacher B.
   • Bein J.
   • Rausch T.
   • et al.
   JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.
   Haematologica. 2019; 104: 330-337
   View in Article

   • Google Scholar
10. • Hartmann S.
    • Eichenauer D.A.
    Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma.
    Pathology. 2020; 52: 142-153
    View in Article

    • Google Scholar
11. • Delsol G.
    • Lamant L.
    • Mariame B.
    • et al.
    A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation.
    Blood. 1997; 89: 1483-1490
    View in Article

    • Google Scholar
12. • Pan Z.
    • Hu S.
    • Li M.
    • et al.
    ALK-positive large B-cell lymphoma: a clinicopathologic study of 26 cases with review of additional 108 cases in the literature.
    Am J Surg Pathol. 2017; 41: 25-38
    View in Article

    • Google Scholar
13. • Laurent C.
    • Do C.
    • Gascoyne R.D.
    • et al.
    Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.
    J Clin Oncol. 2009; 27: 4211-4216
    View in Article

    • Google Scholar
14. • Qunaj L.
    • Castillo J.J.
    • Olszewski A.J.
    Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.
    Leuk Lymphoma. 2018; 59: 1375-1383
    View in Article

    • Google Scholar
15. • Valera A.
    • Colomo L.
    • Martinez A.
    • et al.
    ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.
    Mod Pathol. 2013; 26: 1329-1337
    View in Article

    • Google Scholar
16. • Sakamoto K.
    • Nakasone H.
    • Togashi Y.
    • et al.
    ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.
    Int J Hematol. 2016; 103: 399-408
    View in Article

    • Google Scholar
17. • Mehra V.
    • Pomplum S.
    • Ireland R.
    • et al.
    ALK-positive large B-cell lymphoma with strong CD30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib.
    Histopathology. 2016; 69: 880-882
    View in Article

    • Google Scholar
18. • Chikatsu N.
    • Kojima H.
    • Suzukawa K.
    • et al.
    ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
    Mod Pathol. 2003; 16: 828-832
    View in Article

    • Google Scholar
19. • Onciu M.
    • Behm F.G.
    • Downing J.R.
    • et al.
    ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases.
    Blood. 2003; 102: 2642-2644
    View in Article

    • Google Scholar
20. • Ise M.
    • Kageyama H.
    • Araki A.
    • et al.
    Identification of a novel GORASP2-ALK fusion in an ALK-positive large B-cell lymphoma.
    Leuk Lymphoma. 2019; 60: 493-497
    View in Article

    • Google Scholar
21. • Delecluse H.J.
    • Anagnostopoulos I.
    • Dallenbach F.
    • et al.
    Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection.
    Blood. 1997; 89: 1413-1420
    View in Article

    • Google Scholar
22. • Linke-Serinsoz E.
    • Fend F.
    • Quintanilla-Martinez L.
    Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) related lymphomas, pathology view point.
    Semin Diagn Pathol. 2017; 34: 352-363
    View in Article

    • Google Scholar
23. • Lopez A.
    • Abrisqueta P.
    Plasmablastic lymphoma: current perspectives.
    Blood Lymphat Cancer. 2018; 8: 63-70
    View in Article

    • Google Scholar
24. • Castillo J.J.
    • Bibas M.
    • Miranda R.N.
    The biology and treatment of plasmablastic lymphoma.
    Blood. 2015; 125: 2323-2330
    View in Article

    • Google Scholar
25. • Loghavi S.
    • Alayed K.
    • Aladily T.N.
    • et al.
    Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.
    J Hematol Oncol. 2015; 8: 65
    View in Article

    • Google Scholar
26. • Vega F.
    • Chang C.C.
    • Medeiros L.J.
    • et al.
    Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.
    Mod Pathol. 2005; 18: 806-815
    View in Article

    • Google Scholar
27. • Laurent C.
    • Fabiani B.
    • Do C.
    • et al.
    Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients.
    Haematologica. 2016; 101: 976-984
    View in Article

    • Google Scholar
28. • Pan Z.
    • Chen M.
    • Zhang Q.
    • et al.
    CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall.
    Mod Pathol. 2018; 31: 718-731
    View in Article

    • Google Scholar
29. • Sun J.
    • Medeiros L.J.
    • Lin P.
    • et al.
    Plasmablastic lymphoma involving the penis: a previously unreported location of a case with aberrant CD3 expression.
    Pathology. 2011; 43: 54-57
    View in Article

    • Google Scholar
30. • Valera A.
    • Balagué O.
    • Colomo L.
    • et al.
    IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.
    Am J Surg Pathol. 2010; 34: 1686-1694
    View in Article

    • Google Scholar
31. • Sato S.
    • Teshima S.
    • Nakamura N.
    • et al.
    Intravascular large B-cell lymphoma involving large blood vessels, three autopsy cases.
    Pathol Int. 2019; 69: 97-103
    View in Article

    • Google Scholar
32. • Puckrin R.
    • Pop P.
    • Ghorab Z.
    • et al.
    Intravascular large B-cell lymphoma presenting as Richter's syndrome with cerebral involvement in a patient with chronic lymphocytic leukemia.
    Clin Case Rep. 2017; 5: 1444-1449
    View in Article

    • Google Scholar
33. • Tanaka Y.
    • Kobayashi Y.
    • Maeshima A.M.
    • et al.
    Intravascular large B-cell lymphoma secondary to lymphoplasmacytic lymphoma: a case report and review of literature with clonality analysis.
    Int J Clin Exp Pathol. 2015; 8: 3339-3343
    View in Article

    • Google Scholar
34. • Rajyaguru D.J.
    • Bhaskar C.
    • Borgert A.J.
    • et al.
    Intravascular large B-cell lymphoma in the United States (US): a population-based study using surveillance, epidemiology, and end results program and national cancer database.
    Leuk Lymphoma. 2017; 58: 1-9
    View in Article

    • Google Scholar
35. • Ponzoni M.
    • Campo E.
    • Nakamura S.
    Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks.
    Blood. 2018; 132: 1561-1567
    View in Article

    • Google Scholar
36. • Estalilla O.C.
    • Koo C.H.
    • Brynes R.K.
    • et al.
    Intravascular large B-cell lymphoma. A report of five cases initially diagnosed by bone marrow biopsy.
    Am J Clin Pathol. 1999; 112: 248-255
    View in Article

    • Google Scholar
37. • Khalidi H.S.
    • Brynes R.K.
    • Browne P.
    • et al.
    Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases.
    Mod Pathol. 1998; 11: 983-988
    View in Article

    • Google Scholar
38. • Schrader A.M.R.
    • Jansen P.M.
    • Willemze R.
    • et al.
    High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.
    Blood. 2018; 131: 2086-2089
    View in Article

    • Google Scholar
39. • Ferry J.A.
    • Harris N.L.
    • Picker L.J.
    • et al.
    Intravascular lymphomatosis (malignant angioendotheliomatosis). A B-cell neoplasm expressing surface homing receptors.
    Mod Pathol. 1988; 1: 444-452
    View in Article

    • Google Scholar
40. • Picker L.J.
    • Medeiros L.J.
    • Weiss L.M.
    • et al.
    Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma.
    Am J Pathol. 1988; 130: 496-504
    View in Article

    • Google Scholar
41. • Suzuki Y.
    • Sakakibara A.
    • Shimada K.
    • et al.
    Immune evasion-related extranodal large B-cell lymphoma: a report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
    Pathol Int. 2019; 69: 13-20
    View in Article

    • Google Scholar
42. • Klairmont M.M.
    • Cheng J.
    • Martin M.G.
    • et al.
    Recurrent cytogenetic abnormalities in intravascular large B-cell lymphoma.
    Am J Clin Pathol. 2018; 150: 18-26
    View in Article

    • Google Scholar
43. • Suehara Y.
    • Sakata-Yanagimoto M.
    • Hattori K.
    • et al.
    Liquid biopsy for the identification of intravascular large B-cell lymphoma.
    Haematologica. 2018; 103: e241-e244
    View in Article

    • Google Scholar
44. • Salaverria I.
    • Philipp C.
    • Oschlies I.
    • et al.
    Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe; German High-Grade Lymphoma Study Group; Berlin-Frankfurt-Münster-NHL Trial Group. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.
    Blood. 2011; 118: 139-147
    View in Article

    • Google Scholar
45. • Yu Y.T.
    • Sakata S.
    • Takeuchi K.
    • et al.
    Tonsillar follicular large B-cell lymphoma with IRF4 rearrangement causing sleep apnoea.
    J Clin Pathol. 2019; Jul 19; ([Epub ahead of print])
    View in Article

    • Google Scholar
46. • Chisholm K.M.
    • Mohlman J.
    • Liew M.
    • et al.
    IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials.
    Pediatr Blood Cancer. 2019; 66e27770
    View in Article

    • Google Scholar
47. • Randall C.
    • Fedoriw Y.
    Pathology and diagnosis of follicular lymphoma and related entities.
    Pathology. 2020; 52: 30-39
    View in Article

    • Google Scholar
48. • Salaverria I.
    • Martin-Guerrero I.
    • Burkhardt B.
    • et al.
    High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.
    Genes Chromosomes Cancer. 2013; 52: 150-155
    View in Article

    • Google Scholar
49. • Martelli M.
    • Ferreri A.
    • Di Rocco A.
    • et al.
    Primary mediastinal large B-cell lymphoma.
    Crit Rev Oncol Hematol. 2017; 113: 318-327
    View in Article

    • Google Scholar
50. • Liu P.P.
    • Wang K.F.
    • Xia Y.
    • et al.
    Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis.
    Medicine (Baltimore). 2016; 95e4054
    View in Article

    • Google Scholar
51. • Bledsoe J.R.
    • Redd R.A.
    • Hasserjian R.P.
    • et al.
    The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
    Am J Hematol. 2016; 91: E436-E441
    View in Article

    • Google Scholar
52. • Aladily T.N.
    • Mansour A.
    • Alsughayer A.
    • et al.
    The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma.
    Ann Diagn Pathol. 2019; 40: 72-76
    View in Article

    • Google Scholar
53. • Pileri S.A.
    • Gaidano G.
    • Zinzani P.L.
    • et al.
    Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins.
    Am J Pathol. 2003; 162: 243-253
    View in Article

    • Google Scholar
54. • Rodig S.J.
    • Savage K.J.
    • LaCasce A.S.
    • et al.
    Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.
    Am J Surg Pathol. 2007; 31: 106-112
    View in Article

    • Google Scholar
55. • Gentry M.
    • Bodo J.
    • Durkin L.
    • et al.
    Performance of a commercially available MAL antibody in the diagnosis of primary mediastinal large B-cell lymphoma.
    Am J Surg Pathol. 2017; 41: 189-194
    View in Article

    • Google Scholar
56. • Green M.R.
    • Monti S.
    • Rodig S.J.
    • et al.
    Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Blood. 2010; 116: 3268-3277
    View in Article

    • Google Scholar
57. • Mansouri L.
    • Noerenberg D.
    • Young E.
    • et al.
    Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.
    Blood. 2016; 128: 2666-2670
    View in Article

    • Google Scholar
58. • Wessendorf S.
    • Barth T.F.
    • Viardot A.
    • et al.
    Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH).
    Leukemia. 2007; 21: 2463-2469
    View in Article

    • Google Scholar
59. • Jardin F.
    • Pujals A.
    • Pelletier L.
    • et al.
    Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
    Am J Hematol. 2016; 91: 923-930
    View in Article

    • Google Scholar
60. • Vigano E.
    • Gunawardana J.
    • Mottok A.
    • et al.
    Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation.
    Blood. 2018; 131: 2036-2046
    View in Article

    • Google Scholar
61. • Mottok A.
    • Woolcock B.
    • Chan F.C.
    • et al.
    Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression.
    Cell Rep. 2015; 13: 1418-1431
    View in Article

    • Google Scholar
62. • Mottok A.
    • Hung S.S.
    • Chavez E.A.
    • et al.
    Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.
    Blood. 2019; 134: 802-813
    View in Article

    • Google Scholar
63. • Willemze R.
    • Cerroni L.
    • Kempf W.
    • et al.
    The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.
    Blood. 2019; 133: 1703-1714
    View in Article

    • Google Scholar
64. • Grange F.
    • Beylot-Barry M.
    • Courville P.
    • et al.
    Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
    Arch Dermatol. 2007; 143: 1144-1150
    View in Article

    • Google Scholar
65. • Schrader A.M.R.
    • Jansen P.M.
    • Vermeer M.H.
    • et al.
    High incidence and clinical significance of MYC rearrangements in primary cutaneous diffuse large B-cell lymphoma, leg type.
    Am J Surg Pathol. 2018; 42: 1488-1494
    View in Article

    • Google Scholar
66. • Menguy S.
    • Frison E.
    • Prochazkova-Carlotti M.
    • et al.
    Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas.
    Mod Pathol. 2018; 31: 1332-1342
    View in Article

    • Google Scholar
67. • Robson A.
    • Shukur Z.
    • Ally M.
    • et al.
    Immunocytochemical p63 expression discriminates between primary cutaneous follicle centre cell and diffuse large B cell lymphoma-leg type, and is of the TAp63 isoform.
    Histopathology. 2016; 69: 11-19
    View in Article

    • Google Scholar
68. • Menguy S.
    • Prochazkova-Carlotti M.
    • Beylot-Barry M.
    • et al.
    PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type.
    Am J Surg Pathol. 2018; 42: 326-334
    View in Article

    • Google Scholar
69. • Zhou X.A.
    • Louissaint Jr., A.
    • Wenzel A.
    • et al.
    Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type.
    J Invest Dermatol. 2018; 138: 2365-2376
    View in Article

    • Google Scholar
70. • Pham-Ledard A.
    • Beylot-Barry M.
    • Barbe C.
    • et al.
    High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    JAMA Dermatol. 2014; 150: 1173-1179
    View in Article

    • Google Scholar
71. • Ducharme O.
    • Beylot-Barry M.
    • Pham-Ledard A.
    • et al.
    Mutations of the B-cell receptor pathway confer chemoresistance in primary cutaneous diffuse large B-cell lymphoma leg-type.
    J Invest Dermatol. 2019; 139: 2334-2342
    View in Article

    • Google Scholar
72. • Batchelor T.T.
    Primary central nervous system lymphoma: a curable disease.
    Hematol Oncol. 2019; 37: 15-18
    View in Article

    • Google Scholar
73. • Grommes C.
    • DeAngelis L.M.
    Primary CNS lymphoma.
    J Clin Oncol. 2017; 35: 2410-2418
    View in Article

    • Google Scholar
74. • O'Neill B.P.
    • Decker P.A.
    • Tieu C.
    • et al.
    The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma.
    Am J Hematol. 2013; 88: 997-1000
    View in Article

    • Google Scholar
75. • Guo S.
    • Bai Q.
    • Rohr J.
    • et al.
    Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
    APMIS. 2016; 124: 1054-1062
    View in Article

    • Google Scholar
76. • Liu J.
    • Wang Y.
    • Liu Y.
    • et al.
    Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: analysis of 89 cases.
    Oncol Lett. 2017; 14: 5505-5512
    View in Article

    • Google Scholar
77. • Shi Q.Y.
    • Feng X.
    • Bao W.
    • et al.
    MYC/BCL2 co-expression is a stronger prognostic factor compared with the cell-of-origin classification in primary CNS DLBCL.
    J Neuropathol Exp Neurol. 2017; 76: 942-948
    View in Article

    • Google Scholar
78. • Nayyar N.
    • White M.D.
    • Gill C.M.
    • et al.
    MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.
    Blood Adv. 2019; 3: 375-383
    View in Article

    • Google Scholar
79. • Braggio E.
    • McPhail E.R.
    • Macon W.
    • et al.
    Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens.
    Clin Cancer Res. 2011; 17: 4245-4253
    View in Article

    • Google Scholar
80. • Nosrati A.
    • Monabati A.
    • Sadeghipour A.
    • et al.
    MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Ann Hematol. 2019; 98: 169-173
    View in Article

    • Google Scholar
81. • Zhou Y.
    • Liu W.
    • Xu Z.
    • et al.
    Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes.
    Neoplasia. 2018; 20: 1059-1069
    View in Article

    • Google Scholar
82. • Vater I.
    • Montesinos-Rongen M.
    • Schlesner M.
    • et al.
    The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
    Leukemia. 2015; 29: 677-685
    View in Article

    • Google Scholar
83. • Zorofchian S.
    • El-Achi H.
    • Yan Y.
    • et al.
    Characterization of genomic alterations in primary central nervous system lymphomas.
    J Neurooncol. 2018; 140: 509-517
    View in Article

    • Google Scholar
84. • Munch-Petersen H.D.
    • Asmar F.
    • Dimopoulos K.
    • et al.
    TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Acta Neuropathol Commun. 2016; 4: 40
    View in Article

    • Google Scholar
85. • Zheng M.
    • Perry A.M.
    • Bierman P.
    • et al.
    Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Neuropathology. 2017; 37: 509-516
    View in Article

    • Google Scholar
86. • Nakatsuka S.
    • Yao M.
    • Hoshida Y.
    • et al.
    Pyothorax-associated lymphoma: a review of 106 cases.
    J Clin Oncol. 2002; 20: 4255-4260
    View in Article

    • Google Scholar
87. • Narimatsu H.
    • Ota Y.
    • Kami M.
    • et al.
    Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients.
    Ann Oncol. 2007; 18: 122-128
    View in Article

    • Google Scholar
88. • Aozasa K.
    • Takakuwa T.
    • Nakatsuka S.
    Pyothorax-associated lymphoma: a lymphoma developing in chronic inflammation.
    Adv Anat Pathol. 2005; 12: 324-331
    View in Article

    • Google Scholar
89. • Petitjean B.
    • Jardin F.
    • Joly B.
    • et al.
    Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype.
    Am J Surg Pathol. 2002; 26: 724-732
    View in Article

    • Google Scholar
90. • Nishiu M.
    • Tomita Y.
    • Nakatsuka S.
    • et al.
    Distinct pattern of gene expression in pyothorax-associated lymphoma (PAL), a lymphoma developing in long-standing inflammation.
    Cancer Sci. 2004; 95: 828-834
    View in Article

    • Google Scholar
91. • Boyer D.F.
    • McKelvie P.A.
    • de Leval L.
    • et al.
    Fibrin-associated EBV-positive large B-cell lymphoma: an indolent neoplasm with features distinct from diffuse large B-cell lymphoma associated with chronic inflammation.
    Am J Surg Pathol. 2017; 41: 299-312
    View in Article

    • Google Scholar
92. • Natkunam Y.
    • Goodlad J.R.
    • Chadburn A.
    • et al.
    EBV-positive B-cell proliferations of varied malignant potential: 2015 SH/EAHP Workshop Report - Part 1.
    Am J Clin Pathol. 2017; 147: 129-152
    View in Article

    • Google Scholar
93. • Boroumand N.
    • Ly T.L.
    • Sonstein J.
    • et al.
    Microscopic diffuse large B-cell lymphoma (DLBCL) occurring in pseudocysts: do these tumors belong to the category of DLBCL associated with chronic inflammation?.
    Am J Surg Pathol. 2012; 36: 1074-1080
    View in Article

    • Google Scholar
94. • Katzenstein A.L.
    • Doxtader E.
    • Narendra S.
    Lymphomatoid granulomatosis: insights gained over 4 decades.
    Am J Surg Pathol. 2010; 34: e35-e48
    View in Article

    • Google Scholar
95. • Song J.Y.
    • Pittaluga S.
    • Dunleavy K.
    • et al.
    Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations.
    Am J Surg Pathol. 2015; 39: 141-156
    View in Article

    • Google Scholar
96. • Guinee Jr., D.
    • Jaffe E.
    • Kingma D.
    • et al.
    Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis.
    Am J Surg Pathol. 1994; 18: 753-764
    View in Article

    • Google Scholar
97. • Nador R.G.
    • Cesarman E.
    • Chadburn A.
    • et al.
    Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.
    Blood. 1996; 88: 645-656
    View in Article

    • Google Scholar
98. • Guillet S.
    • Gerard L.
    • Meignin V.
    • et al.
    Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution.
    Am J Hematol. 2016; 91: 233-237
    View in Article

    • Google Scholar
99. • Kim Y.
    • Leventaki V.
    • Bhaijee F.
    • et al.
    Extracavitary/solid variant of primary effusion lymphoma.
    Ann Diagn Pathol. 2012; 16: 441-446
    View in Article

    • Google Scholar
100. • Nam A.S.
     • Tam W.
     An intrasinusoidal extracavitary variant of primary effusion lymphoma.
     Blood. 2017; 130: 836
     View in Article

     • Google Scholar
101. • Chadburn A.
     • Said J.
     • Gratzinger D.
     • et al.
     HHV8/KSHV-positive lymphoproliferative disorders and the spectrum of plasmablastic and plasma cell neoplasms: 2015 SH/EAHP Workshop Report - Part 3.
     Am J Clin Pathol. 2017; 147: 171-187
     View in Article

     • Google Scholar
102. • Yamani F.
     • Chen W.
     Cytokeratin-positive primary effusion lymphoma: a diagnostic challenge.
     Br J Haematol. 2018; 180: 9
     View in Article

     • Google Scholar
103. • Manzano M.
     • Patil A.
     • Waldrop A.
     • et al.
     Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma.
     Nat Commun. 2018; 9: 3263
     View in Article

     • Google Scholar
104. • Ghazarian A.A.
     • Rusner C.
     • Trabert B.
     • et al.
     Testicular cancer among US men aged 50 years and older.
     Cancer Epidemiol. 2018; 55: 68-72
     View in Article

     • Google Scholar
105. • Xu H.
     • Yao F.
     Primary testicular lymphoma: a SEER analysis of 1,169 cases.
     Oncol Lett. 2019; 17: 3113-3124
     View in Article

     • Google Scholar
106. • Ma R.Z.
     • Tian L.
     • Tao L.Y.
     • et al.
     The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience.
     Asian J Androl. 2018; 20: 615-620
     View in Article

     • Google Scholar
107. • Deng L.
     • Xu-Monette Z.Y.
     • Loghavi S.
     • et al.
     Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.
     Leukemia. 2016; 30: 361-372
     View in Article

     • Google Scholar
108. • Twa D.D.W.
     • Mottok A.
     • Savage K.J.
     • et al.
     The pathobiology of primary testicular diffuse large B-cell lymphoma: implications for novel therapies.
     Blood Rev. 2018; 32: 249-255
     View in Article

     • Google Scholar
109. • Williams A.S.
     • Shawwa A.
     • Merrimen J.
     • et al.
     Expression of OCT4 and SALL4 in diffuse large B-cell lymphoma: an analysis of 145 consecutive cases and testicular lymphomas.
     Am J Surg Pathol. 2016; 40: 950-957
     View in Article

     • Google Scholar
110. • Pollari M.
     • Bruck O.
     • Pellinen T.
     • et al.
     PD-L1(+) tumor-associated macrophages and PD-1(+) tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.
     Haematologica. 2018; 103: 1908-1914
     View in Article

     • Google Scholar
111. • Magnoli F.
     • Bernasconi B.
     • Vivian L.
     • et al.
     Primary extranodal diffuse large B-cell lymphomas: many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.
     Cancer Genet. 2018; 228–229: 28-40
     View in Article

     • Google Scholar
112. • Chapuy B.
     • Roemer M.G.
     • Stewart C.
     • et al.
     Targetable genetic features of primary testicular and primary central nervous system lymphomas.
     Blood. 2016; 127: 869-881
     View in Article

     • Google Scholar
113. • Oksenhendler E.
     • Boulanger E.
     • Galicier L.
     • et al.
     High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.
     Blood. 2002; 99: 2331-2336
     View in Article

     • Google Scholar
114. • Auten M.
     • Kim A.S.
     • Bradley K.T.
     • et al.
     Human herpesvirus 8-related diseases: histopathologic diagnosis and disease mechanisms.
     Semin Diagn Pathol. 2017; 34: 371-376
     View in Article

     • Google Scholar
115. • Totonchy J.
     • Osborn J.M.
     • Chadburn A.
     • et al.
     KSHV induces immunoglobulin rearrangements in mature B lymphocytes.
     PLoS Pathol. 2018; 14e1006967
     View in Article

     • Google Scholar
116. • Wang W.
     • Kanagal-Shamanna R.
     • Medeiros L.J.
     Lymphoproliferative disorders with concurrent HHV8 and EBV infection: beyond primary effusion lymphoma and germinotropic lymphoproliferative disorder.
     Histopathology. 2018; 72: 855-861
     View in Article

     • Google Scholar